Shawn T. Estrem

4.1k citations

30 papers · 2.6k indexed · 1 hit paper · h-index 22

Molecular Biology top 5%
Oncology top 2%
Genetics top 5%
Immunology top 10%
Cancer Research top 10%

Co-authors: Tamás Gaál Richard L. Gourse Wilma Ross Ivelina Gueorguieva Ann Cleverly Karim A. Benhadji Michael Lahn Susan C. Guba
Topics: TGF-β signaling in diseases (7 papers)Pancreatic and Hepatic Oncology Research (7 papers)Bacterial Genetics and Biotechnology (5 papers)
Cited by: Oncology Molecular Biology Genetics
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States Spain United Kingdom

In The Last Decade

Shawn T. Estrem

28 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

2015 453 citations Michael Lahn, Ivelina Gueorguieva et al. profile →

Peers

Countries citing papers authored by Shawn T. Estrem

Since Specialization

Citations

This map shows the geographic impact of Shawn T. Estrem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn T. Estrem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn T. Estrem more than expected).

Fields of papers citing papers by Shawn T. Estrem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn T. Estrem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn T. Estrem. The network helps show where Shawn T. Estrem may publish in the future.

Co-authorship network of co-authors of Shawn T. Estrem

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn T. Estrem. A scholar is included among the top collaborators of Shawn T. Estrem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn T. Estrem. Shawn T. Estrem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. 2024 ·Journal of Clinical Oncology ·Manali Bhave,Komal Jhaveri,Peter A. Kaufman,Philippe Aftimos,Janine Lombard,Kostandinos Sideras,Seock‐Ah Im,X. Cynthia,(unknown),Sung‐Bae Kim,Yujia Li,Eunice Yuen,Shawn T. Estrem,Bastien Nguyen,(unknown),(unknown),Muralidhar Beeram,Joohyuk Sohn	0
2	383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study 2023 ·Annals of Oncology ·Komal Jhaveri,(unknown),X. Cynthia,Elgene Lim,Kan Yonemori,Erika Hamilton,(unknown),S-A. Im,(unknown),Sarah Sammons,Manali Bhave,Peter A. Kaufman,C. Saura Manich,Tarek Meniawy,(unknown),Roohi Ismail‐Khan,Yuelin Li,Shawn T. Estrem,(unknown),M. Beeram	9
3	273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2 2023 ·Annals of Oncology ·Patrick Neven,Neil Stahl,María Vidal,M. Martín Jiménez,Peter A. Kaufman,Nadia Harbeck,Kelly K. Hunt,(unknown),(unknown),PA Fasching,Philippe Aftimos,Duncan Wheatley,Erika Hamilton,Rebecca Aft,Swati Kulkarni,Roohi Ismail‐Khan,(unknown),Shawn T. Estrem,Umut Özbek,Eva Ciruelos	4
4	A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer 2023 ·BMC Cancer ·Ernest Nadal,Mansoor N. Saleh,Santiago Ponce Aix,María Ochoa-de-Olza,Sandip Pravin Patel,Scott Antonia,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Shawn T. Estrem,Jiangang Liu,Emin Avşar,Wen Lin,Karim A. Benhadji,Leena Gandhi,Susan C. Guba,Inmaculada Alés Díaz	36
5	Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib 2020 ·PLoS ONE ·Gianluigi Giannelli,Armando Santoro,Robin Kate Kelley,Ed Gane,Valérie Paradis,Ann Cleverly,Claire Smith,Shawn T. Estrem,Michael Man,(unknown),Michael Lahn,Éric Raymond,Karim A. Benhadji,Sandrine Faivre	46
6	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma 2020 ·Investigational New Drugs ·Antje Wick,Annick Desjardins,Cristina Suárez,Peter Forsyth,Ivelina Gueorguieva,(unknown),Ann Cleverly,Shawn T. Estrem,(unknown),Michael Lahn,Susan C. Guba,David Capper,Jordi Rodón	94
7	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. 2019 ·Journal of Clinical Oncology ·Davide Melisi,Antoine Hollebecque,Do‐Youn Oh,Emiliano Calvo,Anna M. Varghese,Erkut Borazanci,T. Macarulla Mercadé,Francesca Simionato,Joon Oh Park,Johanna C. Bendell,Sandrine Faivre,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Shawn T. Estrem,Karim A. Benhadji,Mark C. Lanasa,Susan C. Guba,Rocio García‐Carbonero	26
8	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer 2018 ·British Journal of Cancer ·Davide Melisi,Rocio García‐Carbonero,Teresa Macarulla,Denis Pezet,G. Deplanque,Martin Fuchs,Jörg Trojan,Helmut Oettle,Mark Kozloff,Ann Cleverly,Claire Smith,Shawn T. Estrem,Ivelina Gueorguieva,Michael Lahn,(unknown),Karim A. Benhadji,Josep Tabernero	224
9	First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma 2014 ·Clinical Cancer Research ·Jordi Rodón,Michael A. Carducci,Juan Manuel Sepúlveda-Sánchez,Analía Azaro,Emiliano Calvo,Joan Seoane,Irene Braña,Elisabet Sicart,Ivelina Gueorguieva,Ann Cleverly,(unknown),D. Desaiah,Shawn T. Estrem,Luis Paz‐Ares,Matthias Holdhoff,Jaishri O. Blakeley,Michael Lahn,José Baselga	200
10	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer 2014 ·Investigational New Drugs ·Jordi Rodón,Michael A. Carducci,Juan Manuel Sepúlveda-Sánchez,Analía Azaro,Emiliano Calvo,Joan Seoane,Irene Braña,Elisabet Sicart,Ivelina Gueorguieva,Ann Cleverly,Nischalan Pillay,D. Desaiah,Shawn T. Estrem,Luis Paz‐Ares,Matthias Holdhoff,Jaishri O. Blakeley,Michael Lahn,José Baselga	91
11	Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma 2012 ·Journal of Biological Chemistry ·Vipin Yadav,Xiaoyi Zhang,Jiangang Liu,Shawn T. Estrem,Shuyu Li,Xueqian Gong,Sean G. Buchanan,James R. Henry,James J. Starling,Sheng-Bin Peng	160
12	Assessment of Diet‐induced Obese Rats as an Obesity Model by Comparative Functional Genomics 2008 ·Obesity ·Shuyu Li,Hongyan Zhang,(unknown),Frank Lawrence,(unknown),(unknown),Shawn T. Estrem,John Calley,Gábor Varga,Ernst R. Dow,Yanyun Chen	58
13	Data-driven analysis approach for biomarker discovery using molecular-profiling technologies 2005 ·Biomarkers ·Tao Wei,Birong Liao,Brad Ackermann,Robert A. Jolly,(unknown),Nalini H. Kulkarni,Leah M. Helvering,Keith M. Goldstein,Jianyong Shou,Shawn T. Estrem,Timothy P. Ryan,Jean‐Marie Colet,Craig E. Thomas,James Stevens,J.E. Onyia	9
14	Old and new approaches used to identify gene products important for Saccharomyces cerevisiae cell wall biology 2001 ·Journal of Industrial Microbiology & Biotechnology ·Shawn T. Estrem,Paul L. Skatrud	0
15	Promoter recognition and discrimination by Eσ^S RNA polymerase 2001 ·Molecular Microbiology ·Tamás Gaál,Wilma Ross,Shawn T. Estrem,Lam H. Nguyen,Richard R. Burgess,Richard L. Gourse	151
16	Bacterial promoter architecture: subsite structure of UP elements and interactions with the carboxy-terminal domain of the RNA polymerase alpha subunit 1999 ·Genes & Development ·Shawn T. Estrem,Wilma Ross,Tamás Gaál,(unknown),Wei Niu,Richard H. Ebright,Richard L. Gourse	172
17	Strength and Regulation without Transcription Factors: Lessons from Bacterial rRNA Promoters 1998 ·Cold Spring Harbor Symposia on Quantitative Biology ·Richard L. Gourse,Tamás Gaál,Sarah E. Aiyar,(unknown),Shawn T. Estrem,(unknown),Wilma Ross	24
18	Identification of an UP element consensus sequence for bacterial promoters 1998 ·Proceedings of the National Academy of Sciences ·Shawn T. Estrem,Tamás Gaál,Wilma Ross,Richard L. Gourse	244
19	The Chicken Malic Enzyme Gene: Structural Organization and Identification of Triiodothyronine Response Elements in the 5′-Flanking DNA 1996 ·Archives of Biochemistry and Biophysics ·(unknown),Dominic A. Fantozzi,Debbie C. Thurmond,(unknown),(unknown),Shawn T. Estrem,Gang Xu,Alan Goodridge	28
20	Localization of the intrinsically bent DNA region upstream of theE.coli rrnBP1 promoter 1994 ·Nucleic Acids Research ·Tamás Gaál,Lin Rao,Shawn T. Estrem,Jin Yang,Roger M. Wartell,Richard L. Gourse	36

About Shawn T. Estrem

Shawn T. Estrem is a scholar working on Oncology, Genetics and Molecular Biology, having authored 30 papers that have together received 2.6k indexed citations. Recurring topics across this work include TGF-β signaling in diseases (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Bacterial Genetics and Biotechnology (5 papers). The work is most often cited by research in Oncology (1.0k citations), Molecular Biology (1.6k citations) and Genetics (572 citations). Shawn T. Estrem has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Tamás Gaál, Richard L. Gourse, Wilma Ross, Ivelina Gueorguieva, Ann Cleverly, Karim A. Benhadji, Michael Lahn, Susan C. Guba, Kyla Driscoll and Stephan Herbertz. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact